Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29979613 | 1.00 | ACHE (0.57) | ACHEGABRA1GABRB2MEN1POLB | |
| SCHEMBL19553658 | 1.00 | ACHE (0.57) | ACHEGABRA1GABRB2MEN1POLB | |
| SCHEMBL29980503 | 1.00 | ACHE (0.57) | ACHEGABRA1GABRB2MEN1POLB | |
| SCHEMBL29979392 | 1.00 | ACHE (0.57) | ACHEGABRA1GABRB2MEN1POLB | |
| SCHEMBL22553427 | 1.00 | ACHE (0.57) | ACHEGABRA1GABRB2MEN1POLB | |
| SCHEMBL7591654 | 0.88 | ACHE (0.49) | ACHEGABRA1GABRB2MEN1POLB | |
| SCHEMBL19553846 | 0.85 | ACHE (0.54) | ACHEMETAP1 | |
| SCHEMBL29979377 | 0.85 | ACHE (0.54) | ACHEMETAP1 | |
| SCHEMBL19553584 | 0.82 | ACHE (0.62) | ACHEMAPTMETAP1 | |
| SCHEMBL19553579 | 0.82 | METAP1 (0.43) | ACHEGABRA1GABRB2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563438-B | Organic compounds | 奇华顿股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| EP-3497192-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2021-12-22 | — | — | EP | disclosed |
| US-11020333-B2 | Organic compounds | GIVAUDAN S.A. (CH) | 2021-06-01 | — | — | US | disclosed |
| US-20200330346-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330346-A1 | ORGANIC COMPOUNDS | C5, C1S, CBR3 | ACHE 920/4885GABRA1 3555/4885GABRB2 2860/4885 |
| US-11020333-B2 | Organic compounds | C5, CBR3, C1S | ACHE 928/4885GABRA1 3442/4885GABRB2 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.